Pharvaris (PHVS) Cash & Current Investments (2019 - 2026)
Pharvaris posted quarterly Cash & Current Investments of $341.5 million for Q1 2026, up 15.64% year-on-year from $295.3 million in Q1 2025, and up 0.58% on a QoQ basis from $339.5 million in Q4 2025.
Pharvaris (PHVS) has 8 years of Cash & Current Investments data on file, last reported at $341.5 million in Q1 2026.
- For the quarter ending Q1 2026, Cash & Current Investments rose 15.64% year-over-year to $341.5 million; the trailing twelve-month figure through Mar 2026 stood at $341.5 million (up 15.64% YoY), and the FY2025 full-year result was $329.5 million, up 8.46% from the prior year.
- Cash & Current Investments for Q1 2026 stood at $341.5 million, up from $339.5 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $420.9 million in Q4 2023 and bottomed at $165.1 million in Q4 2022.
- The 5-year median for Cash & Current Investments is $319.8 million (2024), against an average of $310.4 million.
- The widest annual swing landed in 2022, when Cash & Current Investments sank 31.06%; it then surged 154.94% in 2023.
- A 5-year view of Cash & Current Investments shows it stood at $165.1 million in 2022, then soared by 154.94% to $420.9 million in 2023, then fell by 28.73% to $300.0 million in 2024, then gained by 13.18% to $339.5 million in 2025, then advanced by 0.58% to $341.5 million in 2026.
- The last three Cash & Current Investments figures came in at $341.5 million (Q1 2026), $339.5 million (Q4 2025), and $295.3 million (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.13 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.01 Bn |
| 10 | Pharvaris | 267.74 Mn | -73.74 Mn | - | 341.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 341.48 Mn |
| Dec 31, 2025 | 339.53 Mn |
| Mar 31, 2025 | 295.29 Mn |
| Dec 31, 2024 | 299.98 Mn |
| Dec 31, 2023 | 420.94 Mn |
| Dec 31, 2022 | 165.11 Mn |
| Dec 31, 2021 | 239.49 Mn |
| Dec 31, 2020 | 117.59 Mn |
| Dec 31, 2019 | 22.50 Mn |